Add like
Add dislike
Add to saved papers

Incidence of primary cutaneous T-cell lymphoma in Norway.

BACKGROUND: Studies from different countries have reported an increased incidence of primary cutaneous lymphomas over the last decades.

OBJECTIVES: To estimate the incidence rates of primary cutaneous T-cell lymphoma (CTCL) and mycosis fungoides (MF)/Sézary syndrome (SS) in Norway, and to compare these rates with those reported from other countries.

METHODS: Data from the Cancer Registry of Norway on non-Hodgkin lymphomas during the period 1980-2003 were analysed.

RESULTS: In total, 337 cases of CTCL were reported to the Cancer Registry during the study period, of which 262 cases were classified as MF/SS. The incidence rate of CTCL increased significantly (P(trend) < 0.001) from 0.16 (95% confidence interval, CI 0.11-0.20) per 100,000 person-years in 1980-84 to 0.29 (95% CI 0.22-0.36) per 100,000 person-years in 2000-2003. The incidence of MF/SS also increased during the same period (P(trend) = 0.05) from 0.15 (95% CI 0.10-0.19) per 100,000 person-years to 0.18 (95% CI 0.13-0.24) per 100,000 person-years.

CONCLUSIONS: The incidence of both CTCL and MF/SS increased in Norway during the period 1980-2003.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app